Galapagos fails to find suitor, plans exit from cell therapies: Deals Report

Galapagos’ attempt to partner or divest its cell therapy business has proven fruitless, and the Belgian biotech will wind down those operations while seeking new deals as an in-licensing play.

The decision by Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) closes the book on a set of moves in 2022 by then-CEO Paul Stoffels to diversify the company’s business. Once focused on small molecules for inflammation, Stoffels steered Galapagos into a pair of acquisitions, including its purchase of CellPoint B.V. to obtain a cell therapy manufacturing platform...